Kinase News and Research

RSS

Investigating treat-to-target low-density lipoprotein-cholesterol versus high-intensity statins for coronary artery disease

In a recent study published in JAMA, researchers investigated whether treat-to-target (TTT) low-density lipoprotein-cholesterol (LDL-C) therapy was inferior to administering statins of high intensity for clinical outcomes in the long term among coronary artery disease (CAD) patients.

8 Mar 2023

Study identifies a potential new treatment approach for acute myeloid leukemia

A team of researchers has discovered a potential therapeutic that can synergize with existing drugs to more effectively kill certain leukemia cells.

8 Mar 2023

Study reveals a new pathway for how children and adults develop cardiomyopathy

Researchers have discovered how a gene that increases the risk of developing genetic heart disease functions, paving the way for new treatments.

2 Mar 2023

Exploring the neuroprotective potential of cell-penetrating peptides, extracellular vesicles, and micro ribonucleic acids

In a recent review published in Biomedicines, researchers explored extracellular vesicles (EVs), cell-penetrating peptides (CPPs), and micro ribonucleic acids (miRNAs) as therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD).

1 Mar 2023

Breaking apart certain proteins may offer a pathway to treat Alzheimer's diease

Certain diseases, including Alzheimer's, are currently considered "undruggable" because traditional small molecule drugs can't interfere with the proteins responsible for the illnesses.

1 Mar 2023

Significance of mathematical modeling in understanding complex biological processes

Humans and animals detect different stimuli such as light, sound, and odor through nerve cells, which then transmit the information to the brain. Nerve cells must be able to adjust to the wide range of stimuli they receive, which can range from very weak to very strong. To do this, they may become more or less sensitive to stimuli (sensitization and habituation), or they may become more sensitive to weaker stimuli and less sensitive to stronger stimuli for better overall responsiveness (gain control). However, the exact way this happens is not yet understood.

25 Feb 2023

Novel microfluidic model mimics a rare genetic disorder

Our bodies are made up of 60,000 miles of complex pipes that play a vital role in transporting nutrients throughout our bodies, performing waste disposal, and supplying our organs with fresh oxygen and blood.

24 Feb 2023

Exploring the immunomodulatory and anti-inflammatory properties of butyrate

In a recent study published in the journal Fermentation, researchers reviewed studies examining the role of butyrate in inflammatory responses, immunological properties, and diseases related to the immune system such as atopic dermatitis, systemic lupus erythematosus, human immunodeficiency virus (HIV), psoriasis, and cancer.

24 Feb 2023

Researchers reveal the metabolic reactions upon activating Akt2 enzyme

Takeaki Ozawa and his team from the University of Tokyo reveal the metabolic reactions upon activating an enzyme called Akt2. In doing so, they reveal the inner workings of insulin-regulated metabolism.

21 Feb 2023

Researchers use the drug fasudil to reverse two key symptoms of schizophrenia

A team from Nagoya University in Japan used the drug fasudil to reverse two common symptoms associated with schizophrenia: reduced density of pyramidal neurons and cognitive dysfunction associated with methamphetamine treatment.

17 Feb 2023

The prevalence of spike-protein antibodies following at least 3 COVID-19 vaccine doses in immunocompromised individuals

Researchers determined the prevalence of antibodies against the SARS-CoV-2 spike glycoprotein following three or more doses of COVID-19 vaccines among immunocompromised individuals.

17 Feb 2023

Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma

Ipsen (Euronext: IPN; ADR: IPSEY) today announced three-year minimum, 44-month median, follow-up results from the Phase III CheckMate -9ER trial showing that Cabometyx® (cabozantinib) in combination with nivolumab provides survival and response rate benefits after three-years in the first-line treatment of advanced renal cell carcinoma (aRCC), compared to sunitinib.

From Ipsen 14 Feb 2023

Active compound in Lion’s Mane mushroom improves nerve growth and memory

Scientists report that the active compound from an edible mushroom, Hericium erinaceus, can enhance nerve growth and boost memory.

13 Feb 2023

Researcher contextualizes a study on IgG4 anti-Spike levels after repeated SARS-CoV-2 mRNA vaccination

A researchers emphasized the need to reconsider mRNA COVID-19 vaccination strategies in the future,

9 Feb 2023

Novel type of combination therapy shows potential in acute myeloid leukemia

Acute myeloid leukemia (AML) is an aggressive form of cancer that originates in the bone marrow, rapidly spreads to the blood and can quickly cause death if not treated promptly.

7 Feb 2023

USC researchers identify two promising avenues for developing new ALS treatments

Each year in the U.S., 5,000 patients receive a diagnosis of ALS, an incurable neurodegenerative disease that will likely kill them within two to five years.

7 Feb 2023

Recent therapeutic strategies for renal cell carcinoma and the effects of the tumor microenvironment on systemic therapy

Researchers explored the association between the human microbiome and improved renal cell carcinoma outcomes.

6 Feb 2023

ERES IV acquires a majority stake in Oncodesign Services

Oncodesign Services, a leading Contract Research Organization (CRO) specializing in drug discovery and preclinical services in oncology and immuno-inflammation, and Elyan Partners announce the completion of the acquisition of a majority stake in Oncodesign Services by ERES IV, representing 61.58% of its share capital, from its main shareholders, including Mr. Philippe Genne, Founder of Oncodesign Services, as well as certain key shareholders and several managers and minority shareholders, following the entry into exclusive negotiations on June 30, 2022.

From Oncodesign Services 3 Feb 2023

Characterization of Ikaros zinc finger protein 1 mutations in acute myeloid leukemia

Researchers evaluated the clinical and genetic characteristics of acute myeloid leukemia (AML) patients with a mutant Ikaros zinc finger protein 1 (IKZF1).

2 Feb 2023

Researchers devise a novel potential IBD treatment strategy that eliminates pathogenic T cells and encourages the proliferation of regulatory T cells

Researchers investigated the CAMCI strategy as an immunotherapeutic option for inflammatory bowel disease.

31 Jan 2023